List of Excipients in API emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Gilead Sciences Inc | ODEFSEY | emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide | 61958-2101 | CELLULOSE, MICROCRYSTALLINE | 2033-02-15 |
| Gilead Sciences Inc | ODEFSEY | emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide | 61958-2101 | CROSCARMELLOSE SODIUM | 2033-02-15 |
| Gilead Sciences Inc | ODEFSEY | emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide | 61958-2101 | FERROSOFERRIC OXIDE | 2033-02-15 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide
Excipient focus: CELLULOSE, MICROCRYSTALLINE
emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide drug variants containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| Gilead Sciences Inc | emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide | 61958-2101 |
| >Company | >Ingredient | >NDC |
emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CROSCARMELLOSE SODIUM
emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide drug variants containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| Gilead Sciences Inc | emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide | 61958-2101 |
| >Company | >Ingredient | >NDC |
emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide drug variants not containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERROSOFERRIC OXIDE
emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide drug variants containing FERROSOFERRIC OXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Gilead Sciences Inc | emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide | 61958-2101 |
| >Company | >Ingredient | >NDC |
emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide drug variants not containing FERROSOFERRIC OXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: LACTOSE MONOHYDRATE
emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide drug variants containing LACTOSE MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| Gilead Sciences Inc | emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide | 61958-2101 |
| >Company | >Ingredient | >NDC |
emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide drug variants not containing LACTOSE MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide drug variants containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| Gilead Sciences Inc | emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide | 61958-2101 |
| >Company | >Ingredient | >NDC |
emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL
emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide drug variants containing POLYETHYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| Gilead Sciences Inc | emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide | 61958-2101 |
| >Company | >Ingredient | >NDC |
emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide drug variants not containing POLYETHYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYSORBATE 20
emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide drug variants containing POLYSORBATE 20
| Company | Ingredient | NDC |
|---|---|---|
| Gilead Sciences Inc | emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide | 61958-2101 |
| >Company | >Ingredient | >NDC |
emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide drug variants not containing POLYSORBATE 20
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYVINYL ALCOHOL
emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide drug variants containing POLYVINYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| Gilead Sciences Inc | emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide | 61958-2101 |
| >Company | >Ingredient | >NDC |
emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide drug variants not containing POLYVINYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POVIDONE
emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide drug variants containing POVIDONE
| Company | Ingredient | NDC |
|---|---|---|
| Gilead Sciences Inc | emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide | 61958-2101 |
| >Company | >Ingredient | >NDC |
emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide drug variants not containing POVIDONE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TALC
emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide drug variants containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| Gilead Sciences Inc | emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide | 61958-2101 |
| >Company | >Ingredient | >NDC |
emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide drug variants not containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Gilead Sciences Inc | emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide | 61958-2101 |
| >Company | >Ingredient | >NDC |
emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: WATER
emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide drug variants containing WATER
| Company | Ingredient | NDC |
|---|---|---|
| Gilead Sciences Inc | emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide | 61958-2101 |
| >Company | >Ingredient | >NDC |
emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide drug variants not containing WATER
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
© Copyright 2002-2024 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Links
Follow DrugPatentWatch:
